China Resources Pharma Subsidiary Raises Up to RMB1 Billion in 2026 Bond Issue

An update from China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) is now available.

China Resources Pharmaceutical Group has announced that its non-wholly-owned subsidiary, China Resources Double-Crane Pharmaceutical, has completed the first tranche issuance of its 2026 corporate bonds in mainland China to qualified investors. The bonds, with an aggregate principal amount capped at RMB1 billion, carry a three-year term and a coupon rate of 1.65% per annum.

The proceeds from this bond issuance will be directed toward repaying interest-bearing debt and replenishing working capital, which should strengthen the subsidiary’s balance sheet and support ongoing operational needs. The move reflects the group’s continued access to onshore capital markets and may enhance its financial flexibility in China’s competitive pharmaceutical sector, though investors are cautioned to exercise care when trading the company’s securities.

The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.

More about China Resources Pharmaceutical Group Ltd.

China Resources Pharmaceutical Group Limited is a Hong Kong-incorporated pharmaceutical company with operations in mainland China, focusing on the manufacture and distribution of medicines and related healthcare products. Its subsidiary, China Resources Double-Crane Pharmaceutical Co., Ltd., serves the domestic market in the People’s Republic of China through financing and production activities that support its pharmaceutical business.

Average Trading Volume: 11,113,631

Technical Sentiment Signal: Sell

Current Market Cap: HK$31.22B

Find detailed analytics on 3320 stock on TipRanks’ Stock Analysis page.